Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.41 -0.42 (-0.97%)
Streaming Delayed Price Updated: 10:16 AM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
81 82 Next >
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off. 
Via InvestorPlace
Topics Government World Trade
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Earnings Scheduled For February 6, 2025
 
Via Benzinga
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers. 
Via Benzinga
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
From Bristol Myers Squibb
Via Business Wire
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity 
Via MarketBeat
US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch
U.S. stocks could open mixed on Friday. Newell Brands, Flowers Foods, and Plains All American Pipeline to report earnings. 
Via Benzinga
S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
 
Via Benzinga
Topics Stocks
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
 
Via Benzinga
Topics Stocks
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations. 
Via The Motley Fool
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
The company announced plans to generate $2 billion in annual cost savings by the end of 2027. 
Via Stocktwits
Wondering what's happening in today's S&P500 pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans. 
Via Benzinga
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report. 
Via Investor's Business Daily
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s... 
Via StockStory
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst
U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports. 
Via Benzinga
Topics World Trade
Dow Rises Over 300 Points As Nvidia Surges: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
 
Via Benzinga
Topics Stocks
Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday
 
Via Benzinga
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
McDonald's To $290? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.